Annovis Bio, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Annovis Bio has little or no product revenue yet. The diluted share count is up 73.6% on a year earlier, which dilutes existing holders.
Our models give no value for Annovis Bio at present, so past values are not shown.
Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Where it lags: change in share count of 73.6% ranks 147 of 156 biotechnology companies we cover.
Current signal Share count rising (dilution): Diluted shares outstanding rose 73.6% year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Nothing in Annovis Bio, Inc.'s latest figures clears our strength thresholds.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
No model value for Annovis Bio, Inc. at the moment. Current status: no valuation model gives a value we can rate yet. Available reported financials are shown below.
We value Annovis Bio, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.16 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: book value or earnings not available |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no positive revenue in the latest twelve months |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Annovis Bio, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$1.45 | −4% | — | 0% |
| Next | −$0.86 | +41% | — | 0% |
The consensus EPS forecast for the current fiscal year is −19.4% on 90 days ago. In the last 30 days, 1 analyst raised Annovis Bio, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$1.80 | −$1.16 |
| 60 days ago | −$1.80 | −$1.16 |
| 30 days ago | −$1.69 | −$0.89 |
| 7 days ago | −$1.45 | −$0.86 |
| Now | −$1.45 | −$0.86 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.46 | −$0.40 | +13.0% |
| Mar 2026 | −$0.35 | −$0.63 | −80.0% |
| Dec 2025 | −$0.30 | −$0.39 | −30.0% |
| Sept 2025 | −$0.37 | −$0.37 | 0.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| ANVS | +133% | −24% | +39% | −73% | −31% | −69% |
| Industry peers (median) | −36% | −57% | −18% | −28% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| ANVS | 50% | 42% | 42% | 33% | 33% | 0% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| ANVS | −86% | −57% | −75% | −77% | −77% | −76% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since January 29, 2020: 99% from July 13, 2021 to October 19, 2026. Getting back needed a 12501% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 14, 2026 | −2.8% | −0.7% | +1.7% | −37.4% |
| May 15, 2026 | −3.8% | −1.3% | +4.7% | −16.0% |
| March 16, 2026 | +8.7% | +1.3% | −0.8% | −30.2% |
| November 13, 2025 | −3.7% | −1.7% | +59.7% | +55.6% |
| August 12, 2025 | −4.3% | +1.4% | −7.4% | −15.2% |
| May 13, 2025 | +9.0% | +0.8% | +38.1% | +89.7% |
| March 21, 2025 | +2.8% | +1.8% | −8.3% | −18.3% |
| November 12, 2024 | −3.1% | −0.3% | −12.7% | −27.3% |
| August 15, 2024 | +9.9% | +1.9% | +18.4% | +3.4% |
| May 13, 2024 | +41.0% | +0.5% | +47.6% | +2.5% |
| April 3, 2024 | −1.3% | −1.1% | +5.1% | −51.3% |
| November 1, 2023 | −6.8% | +3.0% | −16.0% | +28.4% |
Source: SEC EDGAR filings. Retrieved October 31, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $0 |
| FY23 Q4 | $0 |
| FY24 Q1 | $0 |
| FY24 Q2 | $0 |
| FY24 Q3 | $0 |
| FY24 Q4 | $0 |
| FY25 Q1 | $0 |
| FY25 Q2 | $0 |
| FY25 Q3 | $0 |
| FY25 Q4 | $0 |
| FY26 Q1 | $0 |
| FY26 Q2 | $0 |
| Fiscal year | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −2 | −7 | −15 | −26 | −45 | −27 | −30 | −50 |
| Net income | −1 | −5 | −14 | −25 | −56 | −25 | −29 | −50 |
| Diluted EPS | −$3.51 | −$0.87 | −$1.90 | −$3.10 | −$6.23 | −$2.31 | −$1.40 | −$1.79 |
| Cash flow | ||||||||
| Cash from operations | −0 | −4 | −9 | −17 | −40 | −22 | −26 | −43 |
| Stock-based pay | 0 | 2 | 5 | 9 | 5 | 4 | 2 | 3 |
| Balance sheet | ||||||||
| Cash | 0 | 8 | 46 | 28 | 6 | 11 | 20 | 19 |
| Total debt | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | 0 | −8 | −46 | −28 | −6 | −11 | −20 | −19 |
| Diluted shares | — | 6m | 8m | 8m | 9m | 12m | 21m | 28m |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −4 | −7 | −6 | −6 | −7 | −10 | −18 | −14 |
| Net income | −13 | −6 | −6 | −6 | −7 | −10 | −18 | −15 |
| Diluted EPS | −$0.97 | −$0.42 | −$0.32 | −$0.32 | −$0.37 | −$0.39 | −$0.63 | −$0.40 |
| Cash flow | ||||||||
| Cash from operations | −3 | −8 | −8 | −5 | −3 | −9 | −9 | −22 |
| Stock-based pay | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Change in share count Balance sheet | 73.6% | 7.9% | 147 of 156 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Empery Asset Management, LP | $4.5M | 2.4M | 22.1% | New |
| Marshall Wace, LLP | $3.4M | 1.8M | 17.0% | ▲ 55.1% |
| Vanguard Capital Management LLC | $3.1M | 1.6M | 15.2% | ▲ 88.8% |
| Tudor Investment Corp Et Al | $2.5M | 1.4M | 12.5% | New |
| Renaissance Technologies LLC | $1.9M | 1.0M | 9.2% | ▲ 188.3% |
| Two Sigma Investments, LP | $1.1M | 580K | 5.3% | ▼ 7.7% |
| Geode Capital Management, LLC | $528,134 | 284K | 2.6% | ▲ 14.7% |
| Blackrock, Inc. | $464,732 | 250K | 2.3% | ▲ 79.1% |
| Citadel Advisors LLC | $453,249 | 244K | 2.2% | New |
| Vanguard Fiduciary Trust Co | $330,206 | 178K | 1.6% | ▲ 34.4% |
| Susquehanna International Group, LLP | $273,056 | 147K | 1.4% | ▼ 32.8% |
| Quadrature Capital Ltd | $169,044 | 91K | 0.8% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Annovis Bio, Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Hoffman Michael B Director | May 20, 2026 | Buy | 18,849 | $1.80 | $33,928 |
| Hoffman Michael B Director | May 20, 2026 | Buy | 2,562 | $1.75 | $4,484 |
| Hoffman Michael B Director | May 20, 2026 | Buy | 54,933 | $1.90 | $104,373 |
| Hoffman Michael B Director | April 2, 2026 | Buy | 713,800 | $2.10 | $1.5M |
| Hoffman Michael B Director | December 8, 2025 | Buy | 30,000 | $4.34 | $130,200 |
| Hoffman Michael B Director | December 8, 2025 | Buy | 15,000 | $4.24 | $63,600 |
| Hoffman Michael B Director | November 24, 2025 | Buy | 1,489 | $4.13 | $6,150 |
| Hoffman Michael B Director | November 24, 2025 | Buy | 9,200 | $3.85 | $35,420 |
| Hoffman Michael B Director | November 24, 2025 | Buy | 415 | $4.14 | $1,718 |
| Hoffman Michael B Director | November 24, 2025 | Buy | 28,096 | $4.15 | $116,598 |
| Hoffman Michael B Director | November 24, 2025 | Buy | 9,200 | $3.85 | $35,420 |
| Hoffman Michael B Director | November 24, 2025 | Buy | 415 | $4.14 | $1,718 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
